ELAVL1 and rheumatoid arthritis: Taken together, our results have shown that first, inflammatory bowel diseases and RA modulate m6A-RMRs more than autoimmune lupus and psoriasis; second, autoimmune skin diseases share four upregulated m6A-RMRs including G3BP1, G3BP2, PRRC2A, and WTAP; third, inflammatory bowel diseases share six upregulated m6A-RMRs including ELAVL1, WTAP, ZC3H13, RBM15B, IGF2BP2, and IGF2BP3; and fourth, autoimmune diseases have no any commonly shared m6A-RMRs but share five upregulated m6A-RMRs between groups including PCIF1, G3BP2, G3BP1, WTAP, and FTO.